- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05172726
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Study Overview
Detailed Description
This study is an open-label study, consisting of a 12-week primary treatment phase and an optional 40-week long-term extension phase in which all eligible subjects will receive tapinarof cream, 1% once daily. At the end of the 12-week primary treatment phase subjects will have the option to continue for 40 additional weeks of treatment. Subjects who choose not to participate in the optional 40-week long-term extension phase will complete a follow-up visit approximately one week after the end of the primary treatment phase.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2J7E1
- Dermatology Research Institute Inc.
-
Edmonton, Alberta, Canada, T5J3S9
- Rejuvenation Laser Dermatology Clinics
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1E1V4
- Skincare Studio INC
-
-
Ontario
-
Markham, Ontario, Canada, L3P1X3
- Lynderm Research Inc.
-
Waterloo, Ontario, Canada, N2J 1C4
- Alliance Clinical Trials
-
Whitby, Ontario, Canada, L1P0P9
- Whitby Health Centre Dermatology Trials
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 2V1
- Innovaderm Research, Inc.
-
-
-
-
Arkansas
-
Rogers, Arkansas, United States, 72758
- Northwest Arkansas Clinical Trials Center, PLLC
-
-
California
-
Fountain Valley, California, United States, 92708
- First OC Dermatology
-
Rancho Santa Margarita, California, United States, 92688
- Mission Dermatology Center
-
-
Florida
-
Miami Lakes, Florida, United States, 33014
- San Marcus Research Clinic, Inc.
-
Miami Lakes, Florida, United States, 33014
- RM Medical Research
-
Tampa, Florida, United States, 33615
- Olympian Clinical Research
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Feinberg School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Dawes Fretzin Clinical Research Group
-
West Lafayette, Indiana, United States, 47906
- Options Research Group
-
-
Ohio
-
Fairborn, Ohio, United States, 45324
- Wright State Physicians Pharmacology Translational Unit
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Oregon Dermatology & Research Center
-
-
Washington
-
Spokane, Washington, United States, 99202
- Dermatology Specialists of Spokane
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects ages 2 to 17 years with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 3 months prior to the baseline visit
- Subject with plaque psoriasis covering ≥ 3% of the BSA at screening and baseline
- A PGA score of ≥ 2 at screening and baseline
- Female subjects of childbearing potential who are engaging in sexual activity that could lead to pregnancy should use acceptable birth control methods
- Must not be pregnant
- Subject, subject's parent, or legal representative must be capable of giving written informed consent/assent
Exclusion Criteria:
- Psoriasis other than plaque variant
- Any sign of infection of any of the psoriatic lesions
- Immunocompromised at screening
- Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0x the upper limit of normal (ULN)
- Screening total bilirubin > 1.5x ULN
- Current or chronic history of liver disease
- Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
- Major surgery within 8 weeks prior to baseline or has a major surgery planned during the study
- Known history of clinically significant drug or alcohol abuse in the last year prior to baseline
- Use of any prohibited medication or procedure within the indicated period before the baseline visit until the completion of the study completion or study discontinuation
- History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion may interfere with the subject's participation in the study, interpretation of results, safety of the subject or ability to understand and give informed consent
- Pregnant or lactating females.
- History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation
- Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Open Label
|
applied topically once daily |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of subjects with clinically significant laboratory test abnormalities
Time Frame: Screening up to Week 53
|
Screening up to Week 53
|
|
|
Number of subjects with clinically significant vital signs abnormalities
Time Frame: Screening up to Week 53
|
Screening up to Week 53
|
|
|
Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Screening up to Week 53
|
Incidence, frequency, and duration of treatment emergent AEs and SAEs |
Screening up to Week 53
|
|
Investigator-Assessed Local Tolerability Scale (LTS) Scores
Time Frame: Baseline up to Week 52
|
Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale (0-4). Higher LTS scores represent more severe irritation. |
Baseline up to Week 52
|
|
Subject (or Caregiver)-Assessed Local Tolerability Scale (LTS)
Time Frame: Baseline up to Week 52
|
Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale (0-4). Higher LTS scores represent more severe irritation. |
Baseline up to Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Detectable Time-Point (AUC0-t) of tapinarof cream, 1%.
Time Frame: Week 4 and Week 12
|
Area under the plasma concentration-time curve from time zero to the last quantifiable time point. |
Week 4 and Week 12
|
|
Maximum Plasma Concentration (Cmax) of tapinarof cream, 1%.
Time Frame: Week 4 and Week 12
|
Maximum observed plasma concentration (Cmax). |
Week 4 and Week 12
|
|
Time to Maximum Plasma Concentration (tmax) of tapinarof cream, 1%.
Time Frame: Week 4 and Week 12
|
Time to maximum observed plasma concentration obtained directly from the observed concentration. |
Week 4 and Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Lead Late-Stage Clinical Development, Organon and Co
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DMVT-505-3004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.